Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Regeneron Q1 2026 net income falls 10% to $727m
On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. GAAP diluted earnings per share (EPS) stood at $6.75 while non-GAAP diluted EPS grew 15% year-on-year
On a non-GAAP basis, net income rose 12% to $1.04bn from $928m. GAAP diluted earnings per share (EPS) stood at $6.75 while non-GAAP diluted EPS grew 15% year-on-year
The initiative aligns with China’s and the United Arab Emirates’ (UAE) broader strategic objectives to enhance healthcare and the life sciences industry. The MoU was signed by Arcera
The PRV was awarded after the US Food and Drug Administration (FDA) granted accelerated approval for the Kresladi (marnetegragene autotemcel) gene therapy. Kresladi comprises the patient’s own haematopoietic stem cells that
The deal was originally announced in December 2025. With the acquisition, BioMarin adds two new treatments for lysosomal storage diseases, Galafold (migalastat) for Fabry disease, and Pombiliti (cipaglucosidase alfa-atga) +
The approval allows adults with SLE on standard therapy to inject Saphnelo themselves. It is supported by results from the Phase III TULIP-SC trial, which demonstrated that subcutaneous
The European Commission (EC) has approved Novartis’ Rhapsido (remibrutinib) for certain CSU patients, becoming the first oral treatment for the skin disease. Rhapsido is approved for adult CSU
Organon, created through a spinoff from Merck & Co (MSD) in 2021, distributes more than 70 products across women’s health and general medicines, including biosimilars, reaching 140 countries.
The initiative aims to link external scientific data with internal R&D planning by creating a unified system that supports decision-making, improves market forecasting, and helps prioritise strategic investments.
Under the agreement, Apotex will acquire Cumberland’s branded medicines for cash, subject to approval by Cumberland’s shareholders. The partnership aims to establish a robust platform for speciality medicines
The approval expands the previous indication from those aged eight and above and was granted under a priority review process. This decision is supported by one-year data from